New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 5(6), 525–535 (2006).
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5), 384–386 (2007).
   PubMed Web of Science ®Google Scholar
• Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson’s disease and parkinsonism. Ann. Neurol. 60(4), 389–398 (2006).
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114 (Pt 5), 2283–2301 (1991).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Li YW, Blumbergs PC et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease. Ann. Neurol. 27(4), 373–385 (1990).
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 60(12), 1745–1748 (2003).
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95(11), 6469–6473 (1998).
   PubMed Web of Science ®Google Scholar
• Lee VM, Trojanowski JQ. Mechanisms of Parkinson’s disease linked to pathological α-synuclein: new targets for drug discovery. Neuron 52(1), 33–38 (2006).
   PubMed Web of Science ®Google Scholar
• Guttman M, Burkholder J, Kish SJ et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease: implications for the symptomatic threshold. Neurology 48(6), 1578–1583 (1997).
   PubMed Web of Science ®Google Scholar
• Marek KL, Seibyl JP, Zoghbi SS et al. [123I] β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46(1), 231–237 (1996).
   PubMed Web of Science ®Google Scholar
• DelleDonne A, Klos KJ, Fujishiro H et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 65(8), 1074–1080 (2008).
   PubMedGoogle Scholar
• Lee CS, Samii A, Sossi V et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann. Neurol. 47(4), 493–503 (2000).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann. Neurol. 64(5), 485–491 (2008).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 116(1), 1–16 (2008).
   PubMed Web of Science ®Google Scholar
• Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Controversies over the staging of α-synuclein pathology in Parkinson’s disease. Acta Neuropathol. 116(1), 125–128; author reply 129 (2008).
   PubMed Web of Science ®Google Scholar
• Lang AE. When and how should treatment be started in Parkinson disease? Neurology 72(Suppl. 7), S39–S43 (2009).
   Google Scholar
• Hauser RA, Auinger P, Oakes D; Parkinson Study Group. Levodopa response in early Parkinson’s disease. Mov. Disord. 24(16), 2328–2336 (2009).
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I et al.; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. 351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch. Neurol. 46(10), 1052–1060 (1989).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 328(3), 176–183 (1993).
   PubMed Web of Science ®Google Scholar
• Shoulson I, Oakes D, Fahn S et al.; Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. 51(5), 604–612 (2002).
   PubMed Web of Science ®Google Scholar
• Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis. Assoc. Disord. 10(Suppl. 1), 31–35 (1996).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 361(13), 1268–1278 (2009).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Stern MB. Premotor Parkinson’s disease: clinical features, detection, and prospects for treatment. Ann. Neurol. 64(Suppl. 2), S139–S147 (2008).
   PubMedGoogle Scholar
• Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276(5321), 2045–2047 (1997).
   PubMed Web of Science ®Google Scholar
• Krüger R, Kuhn W, Müller T et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat. Genet. 18(2), 106–108 (1998).
   PubMed Web of Science ®Google Scholar
• Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55(2), 164–173 (2004).
   PubMed Web of Science ®Google Scholar
• Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson’s disease. Annu. Rev. Genomics Hum. Genet. 12, 301–325 (2011).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Eklund AC, Morse LJ et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc. Natl Acad. Sci. USA 104(3), 955–960 (2007).
   PubMed Web of Science ®Google Scholar
• Simón-Sánchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 41(12), 1308–1312 (2009).
   PubMed Web of Science ®Google Scholar
• Li QX, Mok SS, Laughton KM et al. Plasma α-synuclein is decreased in subjects with Parkinson’s disease. Exp. Neurol. 204(2), 583–588 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma α-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J. Neural Transm. 113(10), 1435–1439 (2006).
   PubMed Web of Science ®Google Scholar
• Shi M, Zabetian CP, Hancock AM et al. Significance and confounders of peripheral DJ-1 and α-synuclein in Parkinson’s disease. Neurosci. Lett. 480(1), 78–82 (2010).
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 20(3), 419–425 (2006).
   PubMed Web of Science ®Google Scholar
• Wilhelm KR, Yanamandra K, Gruden MA et al. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson’s disease patients. Eur. J. Neurol. 14(3), 327–334 (2007).
   PubMed Web of Science ®Google Scholar
• Papachroni KK, Ninkina N, Papapanagiotou A et al. Autoantibodies to α-synuclein in inherited Parkinson’s disease. J. Neurochem. 101(3), 749–756 (2007).
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. a-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson’s disease patients. PLoS ONE 6(4), e18513 (2011).
   PubMed Web of Science ®Google Scholar
• Han M, Nagele E, DeMarshall C, Acharya N, Nagele R. Diagnosis of Parkinson’s disease based on disease-specific autoantibody profiles in human sera. PLoS ONE 7(2), e32383 (2012).
   PubMed Web of Science ®Google Scholar
• Hong Z, Shi M, Chung KA et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133(Pt 3), 713–726 (2010).
   PubMed Web of Science ®Google Scholar
• Tokuda T, Qureshi MM, Ardah MT et al. Detection of elevated levels of a-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20), 1766–1772 (2010).
   PubMed Web of Science ®Google Scholar
• Compta Y, Martí MJ, Ibarretxe-Bilbao N et al. Cerebrospinal tau, phospho-tau, and β-amyloid and neuropsychological functions in Parkinson’s disease. Mov. Disord. 24(15), 2203–2210 (2009).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Xie SX, Hurtig H et al. CSF amyloid {β} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75(12), 1055–1061 (2010).
   PubMed Web of Science ®Google Scholar
• Marek K, Jennings D, Lasch S et al., Parkinson Progression Marker I. The Parkinson progression marker initiative (PPMI). Prog. Neurobiol. 95(4), 629–635 (2011).
   PubMed Web of Science ®Google Scholar
• Berg D, Roggendorf W, Schröder U et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59(6), 999–1005 (2002).
   PubMedGoogle Scholar
• Zecca L, Berg D, Arzberger T et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov. Disord. 20(10), 1278–1285 (2005).
   PubMed Web of Science ®Google Scholar
• Ruprecht-Dörfler P, Berg D, Tucha O et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 18(2), 416–422 (2003).
   PubMed Web of Science ®Google Scholar
• Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ. Correlating rates of cerebral atrophy in Parkinson’s disease with measures of cognitive decline. J. Neural Transm. 108(5), 571–580 (2001).
   PubMed Web of Science ®Google Scholar
• Martin WR, Wieler M, Gee M, Camicioli R. Temporal lobe changes in early, untreated Parkinson’s disease. Mov. Disord. 24(13), 1949–1954 (2009).
   PubMed Web of Science ®Google Scholar
• Jubault T, Gagnon JF, Karama S et al. Patterns of cortical thickness and surface area in early Parkinson’s disease. Neuroimage 55(2), 462–467 (2011).
   PubMed Web of Science ®Google Scholar
• Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70(16 Pt 2), 1411–1417 (2008).
   PubMed Web of Science ®Google Scholar
• Péran P, Cherubini A, Assogna F et al. Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 133(11), 3423–3433 (2010).
   PubMed Web of Science ®Google Scholar
• Seibyl JP, Marek KL, Quinlan D et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann. Neurol. 38(4), 589–598 (1995).
   PubMed Web of Science ®Google Scholar
• Booij J, Tissingh G, Boer GJ et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 62(2), 133–140 (1997).
   PubMed Web of Science ®Google Scholar
• Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [18F]β-CFT in assessing disability in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 67(6), 737–741 (1999).
   PubMed Web of Science ®Google Scholar
• Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 55(2), 138–142 (1992).
   PubMed Web of Science ®Google Scholar
• Lanza DC, Deems DA, Doty RL et al. The effect of human olfactory biopsy on olfaction: a preliminary report. Laryngoscope 104(7), 837–840 (1994).
   PubMed Web of Science ®Google Scholar
• Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S. ‘Sniffin’ sticks’: screening of olfactory performance. Rhinology 34(4), 222–226 (1996).
   PubMedGoogle Scholar
• Ross GW, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann. Neurol. 63(2), 167–173 (2008).
   PubMed Web of Science ®Google Scholar
• Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann. Neurol. 56(2), 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 72(Suppl. 7), S21–S26 (2009).
   PubMed Web of Science ®Google Scholar
• Witt M, Bormann K, Gudziol V et al. Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov. Disord. 24(6), 906–914 (2009).
   PubMed Web of Science ®Google Scholar
• Ubeda-Bañon I, Saiz-Sanchez D, de la Rosa-Prieto C, Martinez-Marcos A. a-Synuclein in the olfactory system of a mouse model of Parkinson’s disease: correlation with olfactory projections. Brain Struct. Funct. 217(2), 447–458 (2012).
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 42(4), 726–732 (1992).
   PubMed Web of Science ®Google Scholar
• Singaram C, Ashraf W, Gaumnitz EA et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 346(8979), 861–864 (1995).
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Neunlist M, Bruley des Varannes S et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS ONE 5(9), e12728 (2010).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Keshavarzian A, Mutlu E et al. α-Synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov. Disord. 27(6), 709–715 (2012).
   PubMed Web of Science ®Google Scholar
• Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61(5), 413–426 (2002).
   PubMed Web of Science ®Google Scholar
• Iranzo A, Molinuevo JL, Santamaría J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 5(7), 572–577 (2006).
   PubMed Web of Science ®Google Scholar
• Iranzo A, Valldeoriola F, Lomeña F et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10(9), 797–805 (2011).
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov. Disord. 18(4), 414–418 (2003).
   PubMed Web of Science ®Google Scholar
• Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov. Disord. 15(4), 669–677 (2000).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J. Am. Geriatr. Soc. 52(5), 784–788 (2004).
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C et al.; PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov. Disord. 24(11), 1641–1649 (2009).
   PubMed Web of Science ®Google Scholar
• Woods SP, Tröster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J. Int. Neuropsychol. Soc. 9(1), 17–24 (2003).
   PubMed Web of Science ®Google Scholar
• Azuma T, Cruz RF, Bayles KA, Tomoeda CK, Montgomery EB Jr. A longitudinal study of neuropsychological change in individuals with Parkinson’s disease. Int. J. Geriatr. Psychiatry 18(12), 1115–1120 (2003).
   PubMed Web of Science ®Google Scholar
• Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson’s disease and cognitive decline. J. Clin. Exp. Neuropsychol. 25(1), 94–109 (2003).
   PubMed Web of Science ®Google Scholar
• Levy G, Schupf N, Tang MX et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann. Neurol. 51(6), 722–729 (2002).
   PubMed Web of Science ®Google Scholar
• Richard IH, McDermott MP, Kurlan R et al.; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78(16), 1229–1236 (2012).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatr. 72(6), 708–712 (2002).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med. 351(24), 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatr. 76(7), 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Clark CM, Pontecorvo MJ, Beach TG et al.; AV-45-A16 Study Group. Cerebral PET with florβpir compared with neuropathology at autopsy for detection of neuritic amyloid-b plaques: a prospective cohort study. Lancet Neurol. 11(8), 669–678 (2012).
   PubMed Web of Science ®Google Scholar
• Burn DJ, Rowan EN, Minett T et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov. Disord. 18(8), 884–889 (2003).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Verbaan D, Marinus J, Visser M et al. Cognitive impairment in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 78(11), 1182–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6), 1314–1322 (2005).
   PubMed Web of Science ®Google Scholar
• Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77(3), 288–294 (2011).
   PubMed Web of Science ®Google Scholar
• Xu Q, Park Y, Huang X et al. Physical activities and future risk of Parkinson disease. Neurology 75(4), 341–348 (2010).
   PubMed Web of Science ®Google Scholar
• Li F, Harmer P, Fitzgerald K et al. Tai chi and postural stability in patients with Parkinson’s disease. N. Engl. J. Med. 366(6), 511–519 (2012).
   PubMed Web of Science ®Google Scholar